CA2261630C - Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease - Google Patents

Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease Download PDF

Info

Publication number
CA2261630C
CA2261630C CA2261630A CA2261630A CA2261630C CA 2261630 C CA2261630 C CA 2261630C CA 2261630 A CA2261630 A CA 2261630A CA 2261630 A CA2261630 A CA 2261630A CA 2261630 C CA2261630 C CA 2261630C
Authority
CA
Canada
Prior art keywords
alpha
necrosis factor
tumor necrosis
human tumor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2261630A
Other languages
French (fr)
Other versions
CA2261630A1 (en
Inventor
Marc Feldmann
Ravinder Nath Maini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH
Original Assignee
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24773909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2261630(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kennedy Institute of Rheumotology filed Critical Kennedy Institute of Rheumotology
Priority to CA2791778A priority Critical patent/CA2791778A1/en
Publication of CA2261630A1 publication Critical patent/CA2261630A1/en
Application granted granted Critical
Publication of CA2261630C publication Critical patent/CA2261630C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

Description

ANTI-TNF ANTIBODIES AND METHOTREXATE

Claims (42)

CLAIMS:
1. Use of an anti-human tumor necrosis factor-.alpha. monoclonal antibody or a human tumor necrosis factor-.alpha. binding Fab fragment thereof for the manufacture of a medicament for performing adjunctive therapy with a medicament comprising methotrexate on an individual suffering from rheumatoid arthritis whose active disease is incompletely controlled despite already receiving methotrexate, to reduce or eliminate signs and symptoms associated with the rheumatoid arthritis, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-a binding Fab fragment (a) binds to an epitope on human tumor necrosis factor-.alpha., and (b) inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell surface receptors.
2. Use of an anti-human tumor necrosis factor-.alpha. monoclonal antibody or a human tumor necrosis factor-.alpha. binding Fab fragment thereof for the manufacture of a medicament for performing adjunctive therapy with a medicament comprising methotrexate on an individual suffering from rheumatoid arthritis who still has active disease despite prior therapy with methotrexate and who is already being treated with methotrexate, to reduce or eliminate signs and symptoms associated with the rheumatoid arthritis, wherein the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-a cell surface receptors.
3. The use of claim 1 or 2, wherein the anti-tumor necrosis factor-.alpha. antibody is a chimeric antibody.
4. The use of claim 3, wherein the chimeric antibody binds to the epitope of human tumor necrosis factor-.alpha. recognized by a cA2 antibody.
5. The use of any one of claims 1 to 4, wherein the antibody is infliximab.
6. The use of any one of claims 1 to 5, wherein the anti-human tumor necrosis factor-.alpha. antibody-containing medicament is formulated for administration via infusion.
7. The use of any one of claims 1 to 6, wherein the anti-human tumor necrosis factor-.alpha. antibody or a human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration at an interval of one day to thirty weeks.
8. The use according to any one of claims 1 to 7, wherein the methotrexate-containing medicament is formulated for administration in the form of a series of low doses separated by intervals of days or weeks.
9. The use according to any one of claims 1 to 8, wherein the anti-human tumor necrosis factor-a antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration multiple times, spaced at an interval of weeks.
10. The use of any one of claims 1 to 9, wherein (a) the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration multiple times, spaced at an interval of weeks, and (b) the methotrexate-containing medicament is formulated for administration at intervals of weeks.
11. The use of any one of claims 1 to 10, wherein the methotrexate-containing medicament contains 10 milligrams of methotrexate.
12. The use of any one of claims 1 to 10, wherein (a) the methotrexate-containing medicament contains 7.5mg of methotrexate and is formulated for administration weekly beginning at week 0, and (b) the anti-TNF.alpha. antibody is infliximab and the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration by infusion at weeks 0, 2, 6, 10 and 14.
13. The use according to any one of claims 1 to 12, wherein the anti-tumor necrosis factor .alpha. antibody is a chimeric monoclonal antibody, and the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration as multiple infusions.
14. The use according to any one of claims 1 to 11, wherein (a) the anti- tumor necrosis factor a antibody is infliximab, (b) the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration in combination with the methotrexate-containing medicament as a single infusion of anti-TNF antibody, and (c) the methotrexate-containing medicament contains 10 milligrams of methotrexate.
15. The use according to any one of claims 1 to 11, wherein (a) the anti- tumor necrosis factor a antibody is infliximab, (b) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration as a repeated infusion, and (c) the methotrexate-containing medicament contains 10 milligrams of methotrexate.
16. The use according to any one of claims 1 to 15, wherein the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment is infliximab.
17. A pharmaceutical composition comprising an anti-human tumor necrosis factor-.alpha. monoclonal antibody or a human tumor necrosis factor-.alpha. binding Fab fragment thereof, in admixture with a pharmaceutically acceptable diluent or carrier, for use in performing adjunctive therapy with a medicament comprising methotrexate on an individual suffering from rheumatoid arthritis whose active disease is incompletely controlled despite already receiving methotrexate, to reduce or eliminate signs and symptoms associated with the rheumatoid arthritis, wherein the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment (a) binds to an epitope on human tumor necrosis factor-.alpha., and (b) inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell surface receptors.
18. A pharmaceutical composition comprising an anti-human tumor necrosis factor-.alpha. monoclonal antibody or a human tumor necrosis factor-.alpha. binding Fab fragment thereof, in admixture with a pharmaceutically acceptable diluent or carrier, for use in performing adjunctive therapy with a medicament comprising methotrexate on an individual suffering from rheumatoid arthritis who still has active disease despite prior therapy with methotrexate and who is already being treated with methotrexate, to reduce or eliminate signs and symptoms associated with the rheumatoid arthritis, wherein the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell surface receptors.
19. The pharmaceutical composition of claim 16 or 17, wherein the anti-tumor necrosis factor-.alpha. antibody is a chimeric antibody.
20. The pharmaceutical composition of claim 19, wherein the chimeric antibody binds to the epitope of human tumor necrosis factor-.alpha. recognized by a cA2 antibody.
21. The pharmaceutical composition of any one of claims 17 to 20, wherein the antibody is infliximab.
22. The pharmaceutical composition of any one of claims 17 to 21, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration via infusion.
23. The pharmaceutical composition of any one of claims 17 to 22, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration at an interval of one day to thirty weeks.
24. The pharmaceutical composition of any one of claims 17 to 23, wherein the methotrexate-containing medicament is formulated for administration in the form of a series of low doses separated by intervals of days or weeks.
25. The pharmaceutical composition of any one of claims 17 to 24, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration multiple times, spaced at an interval of weeks.
26. The pharmaceutical composition of any one of claims 17 to 25, wherein (a) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration multiple times, spaced at an interval of weeks and (b) the methotrexate-containing medicament is formulated for administration at intervals of weeks.
27. The pharmaceutical composition of any one of claims 17 to 26, wherein the methotrexate-containing medicament contains 10 milligrams of methotrexate.
28. The pharmaceutical composition of any one of claims 17 to 26, wherein (a) the methotrexate-containing medicament contains 7.5 mg of methotrexate and is formulated for administration weekly beginning at week 0, and (b) the anti-human tumor necrosis factor-.alpha. antibody is infliximab and the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration by infusion at weeks 0, 2, 6, 10 and 14.
29. The pharmaceutical composition of any one of claims 17 to 28, wherein the anti- tumor necrosis factor .alpha. antibody is a chimeric monoclonal antibody, and the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha.
binding Fab fragment-containing medicament is formulated for administration as multiple infusions.
30. The pharmaceutical composition of any one of claims 17 to 27, wherein (a) the anti- tumor necrosis factor a antibody is infliximab, (b) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration in combination with the methotrexate-containing medicament as a single infusion, and (c) the methotrexate-containing medicament contains 10 milligrams of methotrexate.
31. The pharmaceutical composition of any one of claims 17 to 27, wherein (a) the anti- tumor necrosis factor .alpha. antibody is infliximab, (b) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration as a repeated infusion, and (c) the methotrexate-containing medicament contains 10 milligrams of methotrexate.
32. The pharmaceutical composition of any one of claims 17 to 28, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration as a dosage form containing from about 0.1 milligram to about 500 milligrams of the anti anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment.
33. The pharmaceutical composition of any one of claims 17 to 28, wherein the anti-human tumor necrosis factor-.alpha.
antibody is infliximab and the anti-human tumor necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding Fab fragment-containing medicament is formulated for administration as a dosage form containing from about 0.1 milligram to about 500 milligrams of infliximab.
34. The pharmaceutical composition of any one of claims 17 to 33, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab fragment is infliximab.
35. The pharmaceutical composition of any one of claims 17 to 20, wherein the antibody is a humanized antibody.
36. The use of any one of claims 1 to 4, wherein the antibody is a humanized antibody.
37. The use of any one of claims 1 to 4, wherein the antibody is a recombinant antibody.
38. The pharmaceutical composition of any one of claims 17 to 20, wherein the antibody is a recombinant antibody.
39. Use of an anti-human tumor necrosis factor-.alpha. monoclonal antibody for the manufacture of a medicament for performing adjunctive therapy with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage, or improving physical function in an adult patient with moderately to severely active rheumatoid arthritis whose active disease is incompletely controlled despite already receiving methotrexate, wherein the anti-human tumor necrosis factor-.alpha. antibody (a) binds to an epitope on human tumor necrosis factor-.alpha., and (b) inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell surface receptors.
40. Use of an anti-human tumor necrosis factor-.alpha. monoclonal antibody for the manufacture of a medicament for performing adjunctive therapy with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage, or improving physical function in an adult patient with moderately to severely active rheumatoid arthritis who still has active disease despite prior therapy with methotrexate and who is already being treated with methotrexate, wherein the anti-human tumor necrosis factor-.alpha.
antibody inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell surface receptors.
41. A pharmaceutical composition comprising an anti-human tumor necrosis factor-.alpha. monoclonal antibody, in admixture with a pharmaceutically acceptable diluent or carrier, for use in performing adjunctive therapy with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage, or improving physical function in an adult patient with moderately to severely active rheumatoid arthritis whose active disease is incompletely controlled despite already receiving methotrexate, wherein the anti-human tumor necrosis factor-.alpha.
antibody (a) binds to an epitope on human tumor necrosis factor-.alpha., and (b) inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell surface receptors.
42. A pharmaceutical composition comprising an anti-human tumor necrosis factor-.alpha. monoclonal antibody, in admixture with a pharmaceutically acceptable diluent or carrier, for use in performing adjunctive therapy with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage, or improving physical function in an adult patient with moderately to severely active rheumatoid arthritis who still has active disease despite prior therapy with methotrexate and who is already being treated with methotrexate, wherein the anti-human tumor necrosis factor-.alpha. antibody inhibits binding of human tumor necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell surface receptors.
CA2261630A 1996-08-01 1997-08-01 Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease Expired - Lifetime CA2261630C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2791778A CA2791778A1 (en) 1996-08-01 1997-08-01 Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/690,775 1996-08-01
US08/690,775 US6270766B1 (en) 1992-10-08 1996-08-01 Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
PCT/GB1997/002058 WO1998005357A1 (en) 1996-08-01 1997-08-01 Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2791778A Division CA2791778A1 (en) 1996-08-01 1997-08-01 Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
CA2261630A1 CA2261630A1 (en) 1998-02-12
CA2261630C true CA2261630C (en) 2012-12-04

Family

ID=24773909

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2261630A Expired - Lifetime CA2261630C (en) 1996-08-01 1997-08-01 Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
CA2791778A Abandoned CA2791778A1 (en) 1996-08-01 1997-08-01 Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2791778A Abandoned CA2791778A1 (en) 1996-08-01 1997-08-01 Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease

Country Status (11)

Country Link
US (10) US6270766B1 (en)
EP (3) EP1941904B1 (en)
AT (2) ATE305798T1 (en)
AU (1) AU719015B2 (en)
CA (2) CA2261630C (en)
DE (1) DE69734317T2 (en)
DK (3) DK1593393T3 (en)
ES (3) ES2378446T3 (en)
LU (4) LU92005I2 (en)
PT (2) PT1941904E (en)
WO (1) WO1998005357A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
JP3443119B2 (en) * 1989-08-07 2003-09-02 ペプテック リミテッド Tumor necrosis factor binding ligand
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (en) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Human antibodies that bind human tnf alpha.
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EP1352656A3 (en) * 1996-12-06 2004-02-04 Amgen Inc. Combination therapy using a TNF binding protein for treating TNF-mediated diseases
WO1998024463A2 (en) * 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP0980258A1 (en) * 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
EE200100123A (en) * 1998-08-31 2002-06-17 Biogen, Incorporated Use of CD2 binding agent and population of memory effector T lymphocytes
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2001008696A2 (en) * 1999-07-28 2001-02-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
CA2781858C (en) * 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
US20030017150A1 (en) * 2001-03-14 2003-01-23 Torphy Theodore J. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
CN101979095A (en) 2001-05-02 2011-02-23 普渡研究基金会 Treatment and diagnosis of macrophage-mediated diseases
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ATE520400T1 (en) * 2002-11-21 2011-09-15 Genzyme Corp COMBINATION OF A DIAMIDE DERIVATIVE AND IMMUNOSUPRESSIVES FOR SUPPRESSING TRANSPLANT REJECTION
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
AU2003293366A1 (en) * 2002-12-05 2004-06-30 Pharmacia Corporation Engineered fab'fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2004110250A2 (en) 2003-05-30 2004-12-23 Purdue Research Foundation Diagnostic method for atherosclerosis
US7605166B2 (en) * 2003-06-25 2009-10-20 Elan Pharmaceuticals Inc. Methods and compositions for treating rheumatoid arthritis
EP1651266B1 (en) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration of anti-tnf-alpha f(ab')2 antibody fragments
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
TW201705980A (en) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating TNF[alpha]-related disorders
MXPA06012744A (en) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Haplotype markers and methods of using the same to determine response to treatment.
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
US20060111295A1 (en) * 2004-11-22 2006-05-25 Smith Henry J Cellular receptors utilized as carrier agents for pharmaceutical compounds used in the treatment of arthritis, inflammation and immune disorders
RU2007128036A (en) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) METHOD FOR PRODUCING POSITRON-EMISSION TOMOGRAPHY IMAGE
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
AU2016203976B2 (en) * 2005-11-09 2018-02-01 Abt Holding Company Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
CN104027359A (en) 2006-01-23 2014-09-10 阿特西斯公司 MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
MX2008016335A (en) 2006-06-30 2009-01-21 Abbott Biotech Ltd Automatic injection device.
US20080064626A1 (en) * 2006-09-08 2008-03-13 Zanella John M Methods of treating tendonitis in a subject by using an anti-cytokine agent
UA94484C2 (en) 2006-10-12 2011-05-10 Дженентек, Інк. Antibodies to lymphotoxin-alpha
JP2010509570A (en) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション Ex vivo flow cytometry method and apparatus
US8586595B2 (en) * 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
KR20100014565A (en) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2008148001A2 (en) * 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US20100303813A1 (en) 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CA2711984A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
RU2540013C2 (en) * 2008-03-13 2015-01-27 Биотест Аг Agent for treating disease
EP2260057B1 (en) * 2008-03-13 2016-11-23 Biotest AG Anti-CD4 antibody dosage regimen for treating autoimmune disease
EP2265643B1 (en) * 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
BRPI0919489A2 (en) * 2008-09-29 2015-12-01 Biotest Ag composition, kit, methods of treating a rheumatic disease, and rheumatoid arthritis in a patient, agent capable of activating cd4 + cd25 + regulatory t cells and methotrexate, and use of an agent capable of activating cd4 + cd25 + regulatory t cells and methotrexate
WO2010091381A2 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. An intermittent dosing strategy for treating rheumatoid arthrtis
CN102548536A (en) * 2009-10-01 2012-07-04 爱尔康研究有限公司 Olopatadine compositions and uses thereof
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
JP2013512674A (en) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Compositions and methods for increasing the serum half-life of an Fc fusion protein
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING SERIAL HALF LIFE
PH12014500888A1 (en) 2011-11-08 2014-06-09 Arena Pharm Inc Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SI2854769T1 (en) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Methods of treating arthritis
US8958362B2 (en) * 2012-08-24 2015-02-17 William Marsh Rice University Method and system for wirelessly transmitting data
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
DE102012020496A1 (en) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Invitro diagnosis and/or early detection of neurofibromatosis type 1 and/or neurofibromatosis type 1-associated tumor from sample of a patient for treating the patient with the tumor, comprises detecting protein or its fragment in sample
JP6134392B2 (en) 2013-01-25 2017-05-24 サイモン・エルエルシー Compositions for selective reduction of circulating biologically active soluble TNF and methods for treating TNF-mediated diseases
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014182673A1 (en) 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
TWI516272B (en) 2013-06-05 2016-01-11 財團法人工業技術研究院 Method and pharmaceutical composition for hair growth
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10298750B2 (en) * 2013-11-21 2019-05-21 Vodafone Ip Licensing Limited Telecommunication networks for content delivery and lawful interception, content filtering and further content services using a SAVI platform
US9402876B2 (en) 2013-11-27 2016-08-02 Industrial Technology Research Institute Method and pharmaceutical composition for hair growth
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR102372512B1 (en) * 2017-11-20 2022-03-10 가톨릭대학교 산학협력단 Composition for preventing or treating ostarthritis comprising Poly-γ-glutamic acid and methotrexate
WO2023109622A1 (en) * 2021-12-15 2023-06-22 苏州澳宗生物科技有限公司 Use of p75 extracellular domain in treatment and/or prevention of rheumatoid arthritis

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8608068D0 (en) 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
JP2647427B2 (en) 1987-04-24 1997-08-27 帝人株式会社 Detection method, monoclonal antibody, and detection kit for determining disease state of subject
GB8805792D0 (en) 1988-03-11 1988-04-13 Celltech Ltd Medicaments
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
JPH05503919A (en) 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション Suppression of interleukin-1 or tumor necrosis factor production by monocytes and/or macrophages
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
JP3443119B2 (en) 1989-08-07 2003-09-02 ペプテック リミテッド Tumor necrosis factor binding ligand
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
DE69028713T3 (en) 1989-12-27 2004-05-13 Centocor, Inc. CHIMERAL IMMUNOGLOBULINE FOR CD4 RECEPTORS
DE4006269A1 (en) 1990-02-28 1991-08-29 Max Planck Gesellschaft Antibody which binds to tumour necrosis factor receptors
US5204329A (en) * 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GB9023783D0 (en) 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
WO1992008474A2 (en) 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
DE4108204A1 (en) 1991-03-14 1992-09-17 Schering Ag PROCESS FOR THE PREPARATION OF ALKOXYMAGNESIUM HALOGENIDES
EP1857553A1 (en) 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (en) * 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
US5201329A (en) * 1992-01-21 1993-04-13 Claire Quackenbush Permanent wave rod having hinged end-cap
US5580874A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
CA2146647C (en) * 1992-10-08 2009-05-05 Marc Feldmann Treatment of autoimmune and inflammatory disorders
DE4320157A1 (en) * 1993-06-18 1994-12-22 Bayer Ag Use of 1,2,4-dithiazolium salts as chemotherapeutic agents
US5958409A (en) 1993-07-30 1999-09-28 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
JPH09510952A (en) 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー Treatment of autoimmune and inflammatory diseases
AU7965694A (en) 1993-10-15 1995-05-04 Curators Of The University Of Missouri, The Dna encoding the human p2u receptor and null cells expressing p2u receptors
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB2289218A (en) 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530157A (en) * 1995-02-16 1996-06-25 Scios Nova Inc. Anti-inflammatory benzoic acid derivatives
AU2365795A (en) 1995-04-20 1996-11-07 Centocor Inc. Multiple administrations of anti-tnf antibody
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (en) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Human antibodies that bind human tnf alpha.
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
AU2012202134B2 (en) 1996-08-01 2013-02-14 The Kennedy Trust For Rheumatology Research Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
DE19650115C1 (en) 1996-12-03 1998-07-02 Fraunhofer Ges Forschung Medication dosing device
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
EP4006269B1 (en) 2021-11-15 2023-12-27 E-Parktower GmbH Storage/parking device for vehicles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
US8383120B2 (en) 2013-02-26
CA2261630A1 (en) 1998-02-12
LU92099I2 (en) 2013-01-16
DK0914157T3 (en) 2006-01-30
ES2247635T3 (en) 2006-03-01
EP1941904A2 (en) 2008-07-09
EP1941904B1 (en) 2012-05-16
ES2378446T3 (en) 2012-04-12
LU92004I2 (en) 2012-07-23
US8298537B2 (en) 2012-10-30
LU92005I2 (en) 2012-07-23
US20090175859A1 (en) 2009-07-09
AU719015B2 (en) 2000-05-04
US20060099212A1 (en) 2006-05-11
ATE305798T1 (en) 2005-10-15
US7846442B2 (en) 2010-12-07
US20120141474A1 (en) 2012-06-07
ES2388244T3 (en) 2012-10-11
EP1941904A3 (en) 2009-09-09
EP0914157B1 (en) 2005-10-05
US20020010180A1 (en) 2002-01-24
PT1941904E (en) 2012-08-03
US20110123543A1 (en) 2011-05-26
WO1998005357A1 (en) 1998-02-12
ATE535255T1 (en) 2011-12-15
US20020136723A1 (en) 2002-09-26
US6270766B1 (en) 2001-08-07
LU92098I2 (en) 2013-01-16
US20110014188A1 (en) 2011-01-20
EP0914157A1 (en) 1999-05-12
EP1593393A2 (en) 2005-11-09
US7838489B2 (en) 2010-11-23
DK1593393T3 (en) 2012-02-13
DE69734317T2 (en) 2006-07-20
US20130064816A1 (en) 2013-03-14
DE69734317D1 (en) 2006-02-16
DK1941904T3 (en) 2012-07-16
PT1593393E (en) 2012-02-09
HK1020011A1 (en) 2000-03-10
CA2791778A1 (en) 1998-02-12
EP1593393B1 (en) 2011-11-30
US20120141475A1 (en) 2012-06-07
AU3703597A (en) 1998-02-25
EP1593393A3 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
CA2261630C (en) Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
US5741488A (en) Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
Williams et al. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4
EP0783893B1 (en) Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
US6419928B1 (en) Monoclonal antibodies to transforming growth factor-beta and methods of use
US5470571A (en) Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
US8017121B2 (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US8734799B2 (en) Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
US20110020332A1 (en) Prevention of tumors with monoclonal antibodies against neu
WO2002096461A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
RU95112506A (en) METHODS OF TREATMENT, ANTIBODIES AND HYBRIDOMAS
JP2007197458A (en) Tumor necrosis factor binding ligand
EP0927252B1 (en) Antibodies against interferon alpha/beta receptor
Legouffe et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
WO1995009652A1 (en) Treatment of autoimmune and inflammatory disorders
US5084391A (en) Monoclonal antibody to the interleukin-2-receptor and its use
CA2364026A1 (en) Anti-tnf.alpha. antibodies in therapy of asthma
NZ337073A (en) use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
WO1989006967A1 (en) Immunosupression with anti-pan t-cell immunotoxin compositions
EP0303681A1 (en) IMMUNOSUPPRESSION IN THE TREATMENT OF PEOPLE BASED ON IMMUNOTOXIN.
US20020068057A1 (en) Treatment of autoimmune and inflammatory disorders
US7416728B2 (en) Growth blocking agents
Sala et al. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action
JP2025508832A5 (en)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170801